Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VR
Veraxa Biotech AG Ordinary Shares
VRXA
Mkt Cap
$157.4M
Volume
118.96K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VR
VRXA
VR
Veraxa Biotech AG Ordinary Shares
VRXA
News
·
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Mkt Cap
$155.5M
Volume
118.96K
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies.
GlobeNewswire Inc. · Oct 7, 2026
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and biopharmaceutical finance. The appointment comes as VERAXA advances its BiTAC® platform and oncology pipeline toward clinical development.
GlobeNewswire Inc. · Sep 4, 2026
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.
GlobeNewswire Inc. · Jul 6, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
VR
VRXA
Veraxa Biotech AG Ordinary Shares
Buy
Sell
Market
Limit
Soon
VRXA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any VRXA yet.
Related Tickers
Earnings